Advertisement
Jeffrey Lancet, M.D., of the H. Lee Moffitt Cancer Center & ResearchInstitute will present results from Sunesis' Phase 1 clinical trial ofSNS-595, a replication-dependent DNA damaging agent, as part of the oralsession "Acute Myeloid Leukemias: Therapy, excluding Transplantation-NovelTherapies." The presentation, titled "SNS-595 Demonstrates Clinical Responsesin a Phase 1 Study in Acute Leukemia," (Abstract no. 442), will be conductedin RoomA411-A412 at 2:15 p.m. Eastern Time on Monday, December 10, 2007.
Advertisement
In addition, the company will present non-clinical data on SNS-032, acyclin-dependent kinase (CDK) inhibitor, during poster session "CLL: SalvageTherapies and New Agents." The poster, "Mechanism of Action of SNS-032, aNovel Cyclin Dependent Kinase Inhibitor, in Chronic Lymphocytic Leukemia:Comparison with Flavopiridol" (Abstract no. 3112) will be presented in Hall B4of the Georgia World Congress Center on Monday December 10, 2007 from 10:30a.m. to 7:00 p.m.
Conference Call Information
Sunesis management will host a conference call to discuss data beingpresented at the ASH meeting on Monday, December 10, 2007 at 4:00 p.m. EasternTime/1:00 p.m. Pacific Time. Joining management on the call will be clinicalinvestigators involved in the clinical trial of SNS-595and the non-clinicalstudies of SNS-032.
Individual and institutional investors can access the call via877-723-9519 (U.S. and Canada) or 719-325-4841 (international). To access thelive audio webcast, visit the "Investors and Media - Calendar of Events"section of the Sunesis website at http://www.sunesis.com. Please log on toSunesis' website several minutes prior to the start of the presentation toensure adequate time for any software download that may be necessary.
About Sunesis' Oncology Programs
Sunesis has built a rich portfolio of product candidates in oncologyfocused on novel pathways and targets, including inhibition of the cell-cycleand survival signaling. SNS-595, a replication-dependent DNA damaging agent,is currently in Phase 1 and Phase 1b clinical trials of patients with acuteleukemia and a Phase 2 ovarian cancer clinical trial. SNS-032, Sunesis' CDKinhibitor, is being evaluated in a Phase 1 clinical trial in B-cellmalignancies. SNS-314, an Aurora kinase inhibitor, is being studied in aPhase 1 dose-escalating clinical trial in patients with advanced solid tumors.In addition, Sunesis is developing novel small molecule inhibitors of Rafkinase and other oncology kinases in collaboration with Biogen Idec.
About Sunesis Pharmaceuticals
Sunesis is a clinical-stage biopharmaceutical company focused on thediscovery, development and commercialization of novel small moleculetherapeutics for oncology and other serious diseases. Sunesis has built abroad product candidate portfolio through internal discovery and in-licensingof novel cancer therapeutics. Sunesis is advancing its product candidatesthrough in-house research and development efforts and strategic collaborationswith leading pharmaceutical and biopharmaceutical companies. For additionalinformation on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.
SOURCE Sunesis Pharmaceuticals, Inc.
